Abstract
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule Factor Xa inhibitors and thrombin inhibitors. The most advanced drugs reviewed include DPC-423, DPC- 602, razaxaban, GSKs 813893, Portolas Xa inhibitors (formerly Millennium), otamixaban, DU-176b, KFA-1982, BAY- 59-7939, DX-9065a, YM-150, LY-517717, Exanta, 3DPs thrombin inhibitors, SSR-182289, LB-30057, LB-30870, BIBR-1048 and Mercks thrombin inhibitors. With their potentially consistent and predictable pharmacological profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management.
Keywords: Venous thromboembolism, Anticoagulant Agent, DPC-423, Razaxaban, antithrombotic, LY-517717
Current Topics in Medicinal Chemistry
Title: Small Molecule Coagulation Cascade Inhibitors in the Clinic
Volume: 5 Issue: 16
Author(s): Eddine Saiah and Chris Soares
Affiliation:
Keywords: Venous thromboembolism, Anticoagulant Agent, DPC-423, Razaxaban, antithrombotic, LY-517717
Abstract: Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule Factor Xa inhibitors and thrombin inhibitors. The most advanced drugs reviewed include DPC-423, DPC- 602, razaxaban, GSKs 813893, Portolas Xa inhibitors (formerly Millennium), otamixaban, DU-176b, KFA-1982, BAY- 59-7939, DX-9065a, YM-150, LY-517717, Exanta, 3DPs thrombin inhibitors, SSR-182289, LB-30057, LB-30870, BIBR-1048 and Mercks thrombin inhibitors. With their potentially consistent and predictable pharmacological profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management.
Export Options
About this article
Cite this article as:
Saiah Eddine and Soares Chris, Small Molecule Coagulation Cascade Inhibitors in the Clinic, Current Topics in Medicinal Chemistry 2005; 5 (16) . https://dx.doi.org/10.2174/156802605775009702
DOI https://dx.doi.org/10.2174/156802605775009702 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inherited Coagulation Factor VII and X Deficiencies Associated with Severe Bleeding Diathesis: Molecular Genetics and Pathophysiology
Current Genomics Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Ulnar Artery Thrombosis Due to Hypothenar Hammer Syndrome
Recent Patents on Cardiovascular Drug Discovery Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Current Pharmacogenomics and Personalized Medicine Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Mini-Reviews in Medicinal Chemistry Current Treatment Strategies for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Transcatheter Embolization Therapy in Liver Cancer
Recent Patents on Medical Imaging Discovery-Based Strategies for Studying Platelet Function
Mini-Reviews in Medicinal Chemistry Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke
Current Pharmaceutical Design Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Physical and Chemical Stimuli-Responsive Drug Delivery Systems: Targeted Delivery and Main Routes of Administration
Current Pharmaceutical Design Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
Current Medicinal Chemistry What is the Role for Glycoprotein IIB/IIIA Inhibitor Use in the Catheterization Laboratory in the Current Era?
Current Vascular Pharmacology Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Coronary Stent Fracture: A Recently Appreciated Phenomenon with Clinical Relevance
Current Cardiology Reviews The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews ECMO for Refractory Hypoxia; Current State of the Art and Future Directions
Current Respiratory Medicine Reviews